Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

This study is looking at whether a special type of MRI, called Advanced Magnetic Resonance Imaging (AMRI), can help doctors take more accurate biopsies of brain tumors. When you have a brain tumor, some parts can be more aggressive than others. Doctors want to biopsy the most aggressive part to get the best information. Researchers believe AMRI might help them find these aggressive areas better than standard methods. You would have an AMRI scan, which includes different types of imaging like perfusion scans (looking at blood vessels) and spectroscopy scans (looking at the tumor's chemistry), before your scheduled brain tumor removal surgery. The study will compare how well the AMRI-guided biopsies match the actual tumor grade compared to standard biopsies. This study is for adults aged 18 and older who have a suspected or confirmed brain tumor and are scheduled for surgery. The AMRI scan is not yet approved by the FDA and is only used for research.

Study design
This is an interventional study with an unclear phase, planning to enroll up to 62 participants. It is not specified if it is randomized or blinded.
What's involved
You will have an AMRI scan, which takes less than 1 hour, within two weeks before your standard brain tumor removal surgery. During surgery, up to 5 biopsies will be taken from different locations.
Compensation
There will be no cost to you for the advanced MRI, additional anesthesia, special pathology stains, and/or gene testing for this study.
Follow-up
The primary endpoints, which include comparing biopsy accuracy and target sample grading, are measured at 2 weeks after the biopsy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03458676

Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

Recruiting
NAAges 18+InterventionalDiagnostic
M.D. Anderson Cancer Center
~62 participants
Updated 2026-04-15 on ClinicalTrials.gov
What's tested:Advanced Magnetic Resonance Imaging ScanStandard of Care Brain Biopsy and Tumor Removal

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Comparison of the Accuracy of the Pathological Grades of Tumor Observed at the Biopsy Locations Identified Using Conventional Versus Advanced Imaging
Measured over 2 weeks
+1 more outcome measured
Brain Lesion
1 sites across 1 states
Texas1
  • Dawid Schellingerhout, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

electronically, magnetically, and mechanically activated implants
ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators and cardiac pacemakers
metallic splinters in the eye
ferromagnetic hemostatic clips in the central nervous system (CNS) or body
cochlear implants
other pacemakers, e.g., for the carotid sinus
insulin pumps and nerve stimulators
non-MR safe lead wires
prosthetic heart valves (if dehiscence is suspected)
non-ferromagnetic stapedial implants
pregnancy
claustrophobia that does not readily respond to oral medication 4. Allergy to relevant imaging contrast agents, includes allergies to iodine or gadolinium-based contrast agents (if one class of agents is contra-indicated, then imaging with the other can still proceed).
  • Comparison of the Accuracy of the Pathological Grades of Tumor Observed at the Biopsy Locations Identified Using Conventional Versus Advanced Imaging2 weeks

    Researchers wish to determine if the accuracy of the pathological grade observed at the biopsy sites identified by advanced imaging is higher than the grades observed at the biopsy sites identified by conventional imaging.

  • Target Sample Grading2 weeks

    The quantitative pathology markers compared between the conventional and advanced target specimens.